Evidence map›Paper›PMID 39418495›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2025

Patterns of failure with

Samantha Sigurdson, Khalid Al Salman, Aruz Mesci, Ian Dayes, Kimmen Quan, Mira Goldberg, Kara Schnarr, Bobby Shayegan, Glenn Bauman, Katherine Zukotynski and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Samantha SigurdsonMcMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
Khalid Al SalmanMcMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
Aruz MesciUniversity of Toronto and Princess Margaret Cancer Centre, Toronto, ON, Canada.
Ian DayesMcMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
Kimmen QuanMcMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
Mira GoldbergMcMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
Kara SchnarrMcMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
Bobby ShayeganDivision of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada.
Glenn BaumanLondon Health Sciences Centre, London, ON, Canada.
Katherine ZukotynskiDepartments of Medicine and Radiology, McMaster University, Hamilton, ON, Canada.
Theodoros TsakiridisMcMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
Himu LukkaMcMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study aimed to assess the detection rate of prostate cancer recurrence by prostate-specific member antigen-positron emission tomography/computed tomography (PSMA-PET/CT) with

methodsMen from South Central Ontario enrolled in the PSMA Registry for Recurrent Prostate cancer (PREP) between April 2019 and December 2021 after radical prostatectomy (RP) and who had 1) pathologic stage N1 or persistent elevated PSA; or 2) BCR (PSA ≥0.10 ng/mL) where initial postoperative PSA was undetectable were included.

resultsA total of 169 men (median age 68 years; interquartile range [IQR] 62-71) with complete data met the above criteria. The median PSA was 0.27 ng/mL (IQR 0.16-0.85) prior to PSMA-PET. Overall positivity rate 59%; when PSA was <0.40 ng/mL, overall positivity rate 42% vs. 85% with PSA ≥0.40 ng/mL (p<0.001). Higher pathologic tumor stage increased detection of regional lymph nodes (LNs) (pT2-3a: 32% vs. pT3b: 69%, p<0.001) but not distant metastases (pT2-3a: 12% vs. pT3b: 24%, p=0.15). PSMA-PET detected 18% with prostate bed, 42% with regional LN disease, and 44% with pelvic-only disease. The three most involved LN chains were the internal (21%) and external (20%) iliac, and obturator chains (16%).

conclusionsThis prospective study of patients with residual disease or BCR after RP illustrates patterns of failure that could impact diagnosis and postoperative management. Such patients have significant risk of regional LN positivity on PSMA-PET, highlighting a need to include pelvic LNs within salvage radiotherapy volumes.

Identifiers

PMID39418495
PMCPMC11819851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.